Adalimumab (Adalimumab-ADAZ)

Generic Name

Adalimumab-ADAZ

Brand Names

Adalimumab, Adalimumab-bwwd, Amjevita, Hadlima, Hyrimoz, Yusimry

FDA approval date: January 31, 2023

Classification: Tumor Necrosis Factor Blocker

Form: Injection, Kit, Solution

What is Adalimumab (Adalimumab-ADAZ)?

Adalimumab-adaz is a tumor necrosis factor -blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Plaque Psoriasis Adalimumab-adaz is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-adaz should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. Ulcerative Colitis Adalimumab-adaz is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use: The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF-blockers [see Clinical Studies (1.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

Treatment of Rheumatoid Arthritis With Disease-modifying Antirheumatic Drugs (DMARDs): Predictors of Response

Who is this study for: Patients with early rheumatoid arthritis

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Drug

Study Drug: Methotrexate

Study Phase: Phase 3

Summary: Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure. Current treatment goals are to minimize pain, limit joint damage, and prevent loss of function. Drugs used to treat RA include non-steroidal anti-inflammatory drugs (NSAIDS), glucocorticoids, and disease-modifying anti-rheumatic drugs (DMARDs), including biologics...

Efficacy and Safety of Standard-Dose TNF Inhibitor Plus Low-Dose Upadacitinib Versus TNF Inhibitor Intensification for Crohn's Disease With Suboptimal Response to Standard-Dose TNF Inhibitors: A Multicenter, Randomized, Controlled Trial

Enrollment Status: Recruiting

Publish Date: June 09, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of standard-dose tumor necrosis factor inhibitor (TNFi) plus low-dose upadacitinib compared with TNFi dose intensification in patients with moderate-to-severe Crohn's disease who have a suboptimal response to standard-dose TNFi therapy. Eligible participants are adults with active Crohn's disease receiving stan...

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Enrollment Status: Recruiting

Publish Date: June 02, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

View All Clinical Trials